The serine proteases urokinase plasminogen activator and tissue-type plasminogen activator together with their major physiological inhibitor, plasminogen activator inhibitor-1 [PAI-1; serine protease inhibitor clade E member 1 (SERPINE1)] have been identified as prognostic factors for disease progression and relapse in different cancer types since they play important roles in cell adhesion, migration and invasion[81]. Here, SERPINE1 is linked to cancer.